What Cosentyx Treats First
Cosentyx (secukinumab) is primarily designed for plaque psoriasis, a chronic autoimmune skin condition causing red, scaly patches. It's FDA-approved for moderate-to-severe plaque psoriasis in adults and children 6 years and older who need systemic therapy or phototherapy.[1]
How It Works on Skin Conditions
Cosentyx targets interleukin-17A (IL-17A), a protein driving inflammation in psoriasis. This mechanism reduces plaque formation, scaling, and itching, with clinical trials showing clear or almost clear skin in about 80% of patients after 12 weeks.[1][2]
Other Skin Approvals
Beyond plaque psoriasis, Cosentyx is approved for:
- Generalized pustular psoriasis (GPP) flares in adults and children 6+.
- Erythrodermic psoriasis in adults and children 6+.
These are rare, severe forms involving widespread pustules or redness.[1]
Related Conditions It Doesn't Cover
Cosentyx isn't approved for eczema (atopic dermatitis) or common acne, though off-label use occurs rarely. It focuses on IL-17-driven diseases, unlike JAK inhibitors for broader dermatitis.[2]
Who Makes Cosentyx and Patent Status
Novartis manufactures Cosentyx. Key U.S. patents expire in 2027-2031, with challenges from biosimilar developers like Alvotech. Check DrugPatentWatch.com for expiry details and litigation.[3]
[1]: FDA Label - Cosentyx (secukinumab). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf
[2]: Novartis Prescribing Information. https://www.cosentyx.com/plaque-psoriasis
[3]: DrugPatentWatch - Cosentyx Patents. https://www.drugpatentwatch.com/p/tradename/COSENTYX